Highest-materiality recent filing
Completed sale of six consumer brands to Trademark Global for $18M cash; retains Vremi and Xtava.
Board declared a contingent value right (CVR) dividend of one CVR per share of common stock and certain warrants.
Aterian regains Nasdaq minimum bid price compliance; delisting notice closed
Nasdaq notified Aterian on May 19, 2026 it regained compliance with the $1.00 minimum bid price requirement.
Aterian sells marquee brands for $18M cash; Lazar to gain ~95% control via $7M preferred stock
Asset sale: Trademark Global acquires Mueller Living, PurSteam, hOmeLabs, etc. for $18M cash.
Aterian says strategic alternative process progressing; expects update mid-April
Strategic alternative process continues with constructive discussions since December 2025 announcement.
Aterian amends credit agreement, reduces minimum liquidity covenant to $3.5M through April 12
Amendment No. 5 reduces Minimum Credit Party Liquidity covenant to $3.5M, effective through April 12, 2026.
Aterian receives Nasdaq bid price deficiency notice; 180-day cure period until June 2026
Nasdaq notified Aterian on Dec 9, 2025 that closing bid price was below $1.00 for 30 consecutive business days.
Aterian Q3 2025 net revenue $19.0M (down 27% YoY); EBITDA loss narrows sequentially
Net revenue $19.0M vs $26.2M in Q3 2024, down 27% due to tariffs and lower unit volume.
Aterian CTO Roi Zahut resigns effective Nov 3, 2025 for outside executive role
CTO Roi Zahut resigned effective Nov 3, 2025 to accept an outside executive position.
Aterian Q2 net revenue $19.5M (-30% YoY); net loss $4.9M; guides H2 rev $36-38M
Net revenue $19.5M vs $28.0M in Q2 2024; gross margin 54.3% vs 60.4% from tariffs and mix.
Aterian Q1 net revenue falls to $15.4M; withdraws 2025 guidance; CCO departs
Q1 net revenue $15.4M vs $20.2M YoY; net loss improved to $3.9M from $5.2M.
Aterian FY2024 revenue down 31% to $99M; guides 5-7% growth in 2025; launches $3M buyback
Full-year net revenue $99.0M vs $142.6M in 2023; gross margin improved to 62.1% from 49.3%.
Aterian prelim Q4 rev $24.2-25.0M, cash $18M; expects 2025 growth
Preliminary Q4 net revenue $24.2-25.0M (higher end of guidance); anticipates breakeven adjusted EBITDA.
Aterian Q3 net loss improves 71.7% to $1.8M; adjusted EBITDA turns positive at $0.5M
Revenue fell 34% YoY to $26.2M, reflecting reduced product portfolio from SKU rationalization.
Aterian Q2 net loss improves 89.6% YoY; reaches adjusted EBITDA profitability
Net revenue $28.0M, down 20.6% YoY due to SKU rationalization; gross margin improved to 60.4% from 42.2%.
Aterian raises Q2 revenue guidance, announces CEO change, appoints new CFO
Co-CEO Joe Risico resigns; Arturo Rodriguez appointed sole CEO; Josh Feldman named CFO.
Aterian Q1 revenue down 42% to $20.2M, net loss improves 80% to $5.2M loss
Net revenue $20.2M (down 42.0% YoY); gross margin improved to 65.1% from 54.8%.
Aterian improves Q1 2024 revenue and Adjusted EBITDA guidance ranges
Net revenue range improved to $20.0M-$21.0M from prior $18.0M-$21.0M.
Aterian Q4 revenue down 40% to $32.8M; reaffirms H2 2024 adjusted EBITDA profitability
Q4 net revenue $32.8M, down 40.3% YoY; gross margin improved to 51.0% from 37.1%.
Aterian extends credit facility to Dec 2026, reduces liquidity covenant to $6.8M
Revolving commitment reduced to $17M, expandable to $30M if additional tranche fully activated.
Aterian narrows Q4 revenue and EBITDA loss ranges; announces $4M annualized cost savings plan
Q4 net revenue prelim $31.2M-32.0M (prior $28-32M); adj EBITDA loss $(5.5)M-$(6.3)M (improved).
Aterian Q3 net revenue $39.7M, down 40% YoY; net loss improves to $6.3M
Net revenue $39.7M vs $66.3M in Q3 2022, a 40.2% decline.
Aterian raises co-CEOs' base salary to $325k and grants 945,946 restricted shares each
Base salary for co-CEOs Joseph Risico and Arturo Rodriguez increased to $325,000 per annum.
Aterian reports Q2 net revenue down 39.5% to $35.3M, net loss $34.8M, guides Q3 rev $32.5-37.5M
Net revenue $35.3M, down 39.5% YoY; gross margin fell to 42.2% from 53.8%.
Aterian CEO resigns; Q2 revenue guidance cut to $34.8-35.4M; profitability pushed to 2024
CEO Yaniv Sarig resigns; Joe Risico and Arturo Rodriguez appointed Co-CEOs effective July 26.
Proposal to adjourn meeting passed with 26.0M votes for, 7.8M against, 0.3M abstentions.
Aterian Q1 net revenue down 16% to $34.9M, cuts 100 jobs, CFO adds COO role
Q1 net revenue $34.9M vs $41.7M YoY; net loss $(25.8)M vs $(42.8)M; adj. EBITDA loss $(4.3)M.
Aterian receives Nasdaq minimum bid price deficiency notice; 180 days to cure
Nasdaq notified Aterian on April 24, 2023 that its common stock bid price was below $1.00 for 30 consecutive business days.
Aterian updates Q1 2023 revenue range $34-35M, improves adjusted EBITDA loss to ($3.9)-($4.5)M
Q1 net revenue expected between $34.0M and $35.0M, in line with prior guidance.
Q4 2022 net revenue $54.9M, down 13.3% from $63.3M in Q4 2021.
Aterian reports preliminary Q4 revenue $54-55M; CEO takes 80% of 2023 salary in stock
Preliminary Q4 2022 net revenue: $54.0M to $55.0M, at top end of prior projection.
Aterian settles shareholder derivative suit; adopts corporate governance reforms
Settlement of derivative action Zhang v. Aterian et al.; court preliminarily approved Dec 29, 2022.
Aterian Q3 revenue $66.3M, operating loss $(108.9)M, guides Q4 $45-55M
Net revenue $66.3M (-2.6% YoY); gross margin 45.5% vs 50.2%, hit by high-cost inventory liquidation.
Aterian prelim Q3 rev $63-67M, expects $24-29M goodwill impairment, closes $20M direct offering
Preliminary Q3 net revenue $63M-$67M; net loss expected due to operating loss and $24M-$29M non-cash goodwill impairment.
Aterian Q2 2022 revenue down 14.5% to $58.3M; operating loss of $10.1M
Net revenue $58.3M vs $68.2M in Q2 2021; gross margin improved to 53.8% from 48.0%.
Avraham Ben-Tzi was nominated and elected to the Board as a Class II director to serve until the 2027 annual meeting of stockholders or until his successor has been duly elected and qualified.
Accordingly, on July 17, 2026, Lazar was appointed as the Chief Executive Officer of the Company.
On July 17, 2026, immediately following receipt of stockholder approval at the Special Meeting, Bari A. Harlam and Susan Lattmann resigned from the Board (the “ Board Resignations ”).
On July 17, 2026, immediately following receipt of stockholder approval at the Special Meeting, Bari A. Harlam and Susan Lattmann resigned from the Board (the “ Board Resignations ”).
David Natan was nominated and elected to the Board as a Class III director to serve until the 2028 annual meeting of stockholders or until his successor has been duly elected and qualified.
Arturo Rodriguez’s position as the Company’s Chief Executive Officer terminated.
Joshua Feldman, the Company’s Chief Financial Officer, and the Company entered into a Transition and Separation Agreement (the “ Feldman Agreement ”), pursuant to which Mr. Feldman agreed to remain with the Company as its Chief Financial Officer through September 4, 2026.
Lazar will succeed Arturo Rodriguez
the Board increased the authorized number of directors to five and appointed Lazar to the Board to fill the vacancy created by such increase, effective immediately
the Board agreed to appoint Lazar as the sole Chief Executive Officer of the Company promptly following the Second SPA Closing
On May 14, 2025, the Company announced that the employment of Phillip A. Lepper, Chief Commercial Officer of the Company, will end on June 4, 2025.
Mr. William Kurtz and the Company entered into an Advisor Agreement effective August 1, 2024 (the “Advisor Agreement”), pursuant to which Mr. Kurtz shall act as an advisor to senior management of the Company.
Max materiality 0.90 · Median 0.68 · Most common event earnings